Non-alcoholic fatty liver disease: a disease of civilization or a syndrome of modern age?
Tsygankova O.V.1,2, Badin A.R.1, Starichkov A.A.1, Lozhkina N.G.1
1 Novosibirsk State Medical University
2 Research Institute of Therapy and Preventive Medicine, branch of the Federal Research Center of Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences, Novosibirsk
According to WHO prognoses, by 2020 non-alcoholic fatty liver disease (NAFLD) will occupy the first place in the structure of liver diseases. Pandemic character of its prevalence today is proved by the fact that it is found in 37% of the patients who visit general practitioners and therapists. Cirrhosis at the last stage of NAFLD is the second most common cause of the liver transplantation after the cirrhoses of viral etiology. The death rate among these patients is significantly higher than the death rate of those who suffers from cirrhoses of other etiology, along with other transplantation complications, including sepsis, graft rejection and cardiovascular events. This literature review provides information on the pathogenesis of the disease, the importance of the gut microbiota, the relationship between NAFLD and cardiovascular diseases, type 2 diabetes. The article considers the phenotype of NAFLD in patients without concomitant obesity, as well as the concept of metabolic syndrome from the standpoint of local visceral fat depots. The data on the methods of correction is based on clinical guidelines of Russian Gastroenterological Association, Russian Scientific Liver Society, European Association for the Study of the Liver and American Association for the Study of Liver Diseases.
Key words: non-alcoholic fatty liver disease, cardiovascular diseases, insulin resistance, gut microbiome, diabetes, dyslipidemia.
For citation: Tsygankova O.V., Badin A.R., Starichkov A.A., Lozhkina N.G. Non-alcoholic fatty liver disease: a disease of civilization or a syndrome of modern age? // RMJ. Medical Review. 2018. № 3. P. 23–28.
References
1. Benedict M., Zhang X. Non-alcoholic fatty liver disease: An expanded review // World J Hepatol. 2017. Vol. 9 (16). P. 715–732.
2. Ивашкин В. Т., Драпкина О. М., Маев И. В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2 // Рос. журн. гастроэнтерол., гепатол., колопроктол. 2016. Т. 25. № 6. С. 31–41 [Ivashkin V.T., Drapkina O. M., Maev I. V. i dr. Rasprostranennost’ nealkogol’noi zhirovoi bolezni pecheni u patsientov ambulatorno-poliklinicheskoi praktiki v Rossiiskoi Federatsii: rezul’taty issledovaniya DIREG 2 // Ros. zhurn. gastroenterol., gepatol., koloproktol. 2016. T. 25. № 6. S. 31–41 (in Russian)].
3. Мишина Е. Е., Майоров А. Ю., Богомолов П. О. и др. Неалкогольная жировая болезнь печени: причина или следствие инсулинорезистентности? // Сахарный диабет. 2017. Т. 20. № 5. С. 335–343 [Mishina E.E., Maiorov A. Yu., Bogomolov P. O. i dr. Nealkogol’naya zhirovaya bolezn’ pecheni: prichina ili sledstvie insulinorezistentnosti? // Sakharnyi diabet. 2017. T. 20. № 5. S. 335–343 (in Russian)].
4. Day C., James O. Steatohepatitis: A tale of two “hits”? // Gastroenterology. 1998. Vol. 114 (4). P. 842–845.
5. Buzzetti E., Pinzani M., Tsochatzis E. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) // Metabolism. 2016. Vol. 65 (8). P. 1038–1048.
6. Звенигородская Л. А., Шинкин М. В. Неалкогольная жировая болезнь печени и сахарный диабет: мишени метаболического тандема // Consilium medicum. 2015. № 6. С. 31–41 [Zvenigorodskaya L.A., Shinkin M. V. Nealkogol’naya zhirovaya bolezn’ pecheni i sakharnyi diabet: misheni metabolicheskogo tandema // Consilium medicum. 2015. № 6. S. 31–41 (in Russian)].
7. Цыганкова О. В., Соколова Т. А., Латынцева Л. Д., Воевода С. М. Синдром холестаза в практике врача-интерниста // РМЖ. 2017. № 2. С. 110–112 [Tsygankova O.V., Sokolova T. A., Latyntseva L. D., Voevoda S. M. Sindrom kholestaza v praktike vracha-internista // RMZh. 2017. № 2. S. 110–112 (in Russian)].
8. Castera L. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough // Liver International. 2018. Vol. 38. P. 67–70. doi:10.1111/liv.13658.
9. Ridaura V.K., Faith J.J., Rey F.E. et al. Gut microbiota fr om twins discordant for obesity modulate metabolism in mice // Science. 2013. Vol. 341(6150). P. 1241214.
10. Walker A., Parkhill J. Fighting Obesity with Bacteria // Science. 2013. Vol. 341 (6150). P. 1069–1070.
11. Vrieze A., Van Nood E., Holleman F. et al. Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome // Gastroenterology. 2012. Vol. 143 (4). P. 913–916.
12. De Bandt J., Waligora-Dupriet A., Butel M. Intestinal microbiota in inflammation and insulin resistance: relevance to humans // Curr Opin Clin Nutr Metab Care. 2011. Vol. 14 (4). P. 334–340.
13. Кожевников А. А., Раскина К. В., Мартынова Е. Ю. и др. Связь состояния кишечной микробиоты с заболеваниями человека и трансплантация микробиоты как способ восстановления ее нормального состава // РМЖ. 2017. № 2. С. 92–98 [Kozhevnikov A.A., Raskina K. V., Martynova E. Yu. i dr. Svyaz’ sostoyaniya kishechnoi mikrobioty s zabolevaniyami cheloveka i transplantatsiya mikrobioty kak sposob vosstanovleniya ee normal’nogo sostava // RMZh. 2017. № 2. S. 92–98 (in Russian)].
14. Mokhtari Z., Gibson D., Hekmatdoost A. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet // Advances in Nutrition: An International Review Journal. 2017. Vol. 8 (2). P. 240–252.
15. Kallus S., Brandt L. The Intestinal Microbiota and Obesity // J Clin Gastroenterol. 2012. Vol. 46 (1). P. 16–24.
16. Doulberis M., Kotronis G., Gialamprinou D. et al. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota // Metabolism. 2017. Vol. 71. P. 182–197.
17. Костюкевич О. И., Былова Н. А., Симбирцева А. С. Роль кишечной микробиоты в развитии заболеваний печени и желчевыводящих путей // РМЖ. 2016. № 11. С. 713–720 [Kostyukevich O.I., Bylova N. A., Simbirtseva A. S. Rol’ kishechnoi mikrobioty v razvitii zabolevanii pecheni i zhelchevyvodyashchikh putei // RMZh. 2016. № 11. S. 713–720 (in Russian)].
18. Leung C., Rivera L., Furness J., Angus P. The role of the gut microbiota in NAFLD // Nature Reviews Gastroenterology & Hepatology. 2016. Vol. 13 (7). P. 412–425.
19. Piepoli M., Hoes A., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice // Eur Heart J. 2016. Vol. 37 (29). P. 2315–2381.
20. Чумакова Г. А., Веселовская Н. Г. Клиническое значение висцерального ожирения. М.: ГЭОТАР-Медиа, 2016. 160 с. [Chumakova G.A., Veselovskaya N. G. Klinicheskoe znachenie vistseral’nogo ozhireniya. M.: GEOTAR-Media, 2016. 160 s. (in Russian)].
21. Чумакова Г. А., Веселовская Н. Г., Козаренко А. А., Барбараш Л. С. Локальные жировые депо как фактор риска сердечно-сосудистых заболеваний // Артериальная гипертензия. 2010. Т. 15. № 5. C. 441–448 [Chumakova G.A., Veselovskaya N. G., Kozarenko A. A., Barbarash L. S. Lokal’nye zhirovye depo kak faktor riska serdechno-sosudistykh zabolevanii // Arterial’naya gipertenziya. 2010. T. 15. № 5. C. 441–448 (in Russian)].
22. Perseghin G. Viewpoints on the Way to a Consensus Session: Wh ere does insulin resistance start? The liver // Diabetes Care. 2009. Vol. 32 (2). P. 164–167.
23. Романцова Т. И., Островская Е. В. Метаболически здоровое ожирение: дефиниции, протективные факторы, клиническая значимость // Альманах клинической медицины. 2015. № S1. С.75–86 [Romantsova T.I., Ostrovskaya E. V. Metabolicheski zdorovoe ozhirenie: definitsii, protektivnye faktory, klinicheskaya znachimost’ // Al’manakh klinicheskoi meditsiny. 2015. № S1. S. 75–86 (in Russian)].
24. Kotronen A., Seppälä-Lindroos A., Bergholm R., Yki-Järvinen H. Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome // Diabetologia. 2007. Vol. 51 (1). P. 130–138.
25. Yki Järvinen H. Fat in the liver and insulin resistance // Ann Med. 2005. Vol. 37 (5). P. 347–356.
26. Драпкина О. М., Корнеева О. Н. Континуум неалкогольной жировой болезни печени: от стеатоза печени до сердечно-сосудистого риска // Рациональная фармакотерапия в кардиологии. 2016. Т. 12. № 4. С. 424–429 [Drapkina O.M., Korneeva O. N. Kontinuum nealkogol’noi zhirovoi bolezni pecheni: ot steatoza pecheni do serdechno-sosudistogo riska // Ratsional’naya farmakoterapiya v kardiologii. 2016. T. 12. № 4. S. 424–429 (in Russian)].
27. Цыганкова О. В., Бондарева З. Г., Пипия Х. Г. и др. Кальциноз сердца и сосудов. Актуальность проблемы. Современные возможности визуализации // Вестник новых медицинских технологий. 2011. Т. 18. № 3. С. 86–90 [Tsygankova O.V., Bondareva Z. G., Pipiya Kh.G. i dr. Kal’tsinoz serdtsa i sosudov. Aktual’nost’ problemy. Sovremennye vozmozhnosti vizualizatsii // Vestnik novykh meditsinskikh tekhnologii. 2011. T. 18. № 3. S. 86–90 (in Russian)].
28. Kim H., Cho Y. Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease // The Korean Journal of Gastroenterology. 2017. Vol. 69 (6). P. 333.
29. Athyros V., Tziomalos K., Katsiki N. et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update // World J Gastroenterol. 2015. Vol. 21 (22). P. 6820–6834.
30. Mikolasevic I, Milic S, Turk Wensveen T et al. Nonalcoholic fatty liver disease — A multisystem disease? // World J Gastroenterol. 2016. Vol. 22 (43). P. 9488.
31. Mantovani A., Ballestri S., Lonardo A., Targher G. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease // Dig Dis Sci. 2016. Vol. 61 (5). P. 1246–1267.
32. Madan S., John F., Pyrsopoulos N., Pitchumoni C. Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults // Eur J Gastroenterol Hepatol. 2015. Vol. 27 (11). P. 1237–1248.
33. Mantovani A. Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis // J Clin Transl Hepatol. 2017. Vol. 20 (20). P. 1–8.
34. Ахмедов В. А. Неалкогольная жировая болезнь печени и вероятность развития нарушений сердечного ритма // РМЖ. 2017. № 20. С. 1486–1488 [Akhmedov V. A. Nealkogol’naya zhirovaya bolezn’ pecheni i veroyatnost’ razvitiya narushenii serdechnogo ritma // RMZh. 2017. № 20. S. 1486–1488 (in Russian)].
35. Du T., Sun X., Yuan G. et al. Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors // Nutrition, Metabolism and Cardiovascular Diseases. 2017. Vol. 27 (1). P. 63–69.
36. Цыганкова О. В., Николаев К. Ю., Федорова Е. Л. и др. Факторы риска сердечно-сосудистых заболеваний. Взгляд на женщину // Атеросклероз. 2014. Т. 10. № 1. С. 44–55 [Tsygankova O.V., Nikolaev K. Yu., Fedorova E. L. i dr. Faktory riska serdechno-sosudistykh zabolevanii. Vzglyad na zhenshchinu // Ateroskleroz. 2014. T. 10. № 1. S. 44–55 (in Russian)].
37. Min H., Kapoor A., Fuchs M. et al. Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease // Cell Metab. 2012. Vol. 15 (5). P. 665–674.
38. Targher G., Bertolini L., Rodella S. et al. Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Cardiovascular Events in Type 2 Diabetic Patients // Diabetes Care. 2007. Vol. 30 (8). P. 2119–2121.
39. Anstee Q., Targher G., Day C. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis // Nature Reviews Gastroenterology & Hepatology. 2013. Vol. 10 (6). P. 330–344.
40. Targher G., Bertolini L., Rodella S. et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients // Diabetologia. 2007. Vol. 51 (3). P. 444–450.
41. Lomonaco R., Bril F., Portillo-Sanchez P. et al. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes // Diabetes Care. 2016. Vol. 39 (4). P. 632–638.
42. Шаронова Л. А., Вербовой А. Ф., Вербовая Н. И., Пашенцева А. В. Взаимосвязь неалкогольной жировой болезни печени и сахарного диабета 2-го типа // РМЖ. 2017. № 22. С. 1635–1640 [Sharonova L.A., Verbovoi A. F., Verbovaya N. I., Pashentseva A. V. Vzaimosvyaz’ nealkogol’noi zhirovoi bolezni pecheni i sakharnogo diabeta 2-go tipa // RMZh. 2017. № 22. S. 1635–1640 (in Russian)].
43. Anstee Q., Targher G., Day C. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis // Nature Reviews Gastroenterology & Hepatology. 2013. Vol. 10 (6). P. 330–344.
44. Kim D., Kim W. Nonobese Fatty Liver Disease // Clinical Gastroenterology and Hepatology. 2017. Vol. 15 (4). P. 474–485.
45. Sookoian S., Pirola C. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease // Aliment Pharmacol Ther. 2017. Vol. 47 (1). P. 16–25.
46. VanWagner L., Armstrong M. Lean NAFLD: A not so benign condition? // Hepatology Communications. 2018. Vol. 2 (1). P. 5–8.
47. Sookoian S., Pirola C. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients // Aliment Pharmacol Ther. 2017. Vol. 46 (2). P. 85–95.
48. Kumar R., Mohan S. Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications // J Clin Transl Hepatol. 2017. Vol. 20 (20). P. 1–8.
49. Wattacheril J., Sanyal A. Lean NAFLD: an Underrecognized Outlier // Curr Hepatol Rep. 2016. Vol. 15 (2). P. 134–139.
50. Feldman A., Eder S., Felder T. et al. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver // Am J Gastroenterol. 2016. Vol. 112 (1). P. 102–110.
51. Feldman A., Eder S., Felder T. et al. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver // Am J Gastroenterol. 2016. Vol. 112 (1). P. 102–110.
52. Hashimoto Y., Hamaguchi M., Fukuda T. et al. Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals // Endocrine. 2017. Vol. 57 (1). P. 89–97.
53. Ивашкин В. Т., Маевская М. В., Павлов Ч. С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016. Т. 26. № 2. С. 24–42 [Ivashkin V.T., Maevskaya M. V., Pavlov Ch.S. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniyu nealkogol’noi zhirovoi bolezni pecheni Rossiiskogo obshchestva po izucheniyu pecheni i Rossiiskoi gastroenterologicheskoi assotsiatsii // Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2016. T. 26. № 2. S. 24–42 (in Russian)].
54. Mills E., Brown K., Smith J. et al. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety // Ther Adv Endocrinol Metab. 2017. Vol. 9 (1). P. 15–28.
55. Hadi H., Vettor R., Rossato M. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? // Antioxidants. 2018. Vol. 7 (1). P. 12.
56. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease // J Hepatol. 2016. Vol. 64 (6). P. 1388–1402.
57. Armstrong M., Gaunt P., Aithal G. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study // The Lancet. 2016. Vol. 387 (10019). P. 679–690.
58. Chalasani N., Younossi Z., Lavine J. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Disease // Hepatology. 2017. Vol. 67 (1). P. 328–357.
59. Тишковский С. В., Давыдчик Э. В., Никонова Л. В. Неалкогольная жировая болезнь печени и сахарный диабет 2 типа — звенья одного процесса // Журнал ГрГМУ. 2016. № 1. C. 92–98 [Tishkovskii S.V., Davydchik E. V., Nikonova L. V. Nealkogol’naya zhirovaya bolezn’ pecheni i sakharnyi diabet 2 tipa — zven’ya odnogo protsessa // Zhurnal GrGMU. 2016. № 1. C. 92–98 (in Russian)].
60. Marchesini G., Day Ch.P., Dufour J. F. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease // J Hepatol. 2016. Vol. 64 (6). P. 1388–1402.
61. Ивашкин В. Т., Маевская М. В., Павлов Ч. С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. 2016. № 2. С. 24–42 [Ivashkin V.T., Mayevskaya M. V., Pavlov CH.S. i dr. Klinicheskiye rekomendatsii po diagnostike i lecheniyu nealkogol’noy zhirovoy bolezni pecheni Rossiyskogo obshchestva po izucheniyu pecheni i Rossiyskoy gastroenterologicheskoy assotsiatsii. 2016. № 2. S. 24–42 (in Russian)].
62. Лазебник Л. Б., Радченко В. Г., Голованова Е. В. и др. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение (рекомендации для терапевтов, 2-я версия) // Терапия. 2017. № 3 (13). С. 6–23 [Lazebnik L.B., Radchenko V. G., Golovanova E. V. i dr. Nealkogol’naja zhirovaja bolezn’ pecheni: klinika, diagnostika, lechenie (rekomendacii dlja terapevtov, 2-ja versija). // Terapija. 2017. № 3 (13). S. 6–23 (in Russian)].
63. Younossi Z., Loomba R., Rinella M. et al. Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) // Hepatology. 2017. doi:10.1002/hep.29724.
64. Issa D., Patel V., Sanyal A. Future therapy for non-alcoholic fatty liver disease // Liver International. 2018. Vol. 38. P. 56–63.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
